MHealth Summit 2014 Executive Spotlight: Kaiser Permanente – Video



MHealth Summit 2014 Executive Spotlight: Kaiser Permanente
Christine Paige, Senior Vice President of Marketing Internet Services speaks to Health Care Pulse E-Magazine reporter about Kaiser's position on mobile health and additional tools coming…

By: Health Care Pulse E-Magazine

Here is the original post:

MHealth Summit 2014 Executive Spotlight: Kaiser Permanente – Video

LEO Pharma A/S announces regulatory submission of ENSTILAR for psoriasis in Europe

Published on March 26, 2015 at 12:30 PM

ENSTILAR has the potential to be the first cutaneous foam approved for the treatment of psoriasis vulgaris.

LEO Pharma A/S today announced it submitted a Marketing Authorisation Application for Enstilar (calcipotriol/betamethasone dipropionate 50 micrograms/g / 0,5 mg/g) cutaneous foam for the treatment of psoriasis vulgaris, a chronic, inflammatory skin disease that can significantly impact quality of life for patients to 30 European health authorities.

The new cutaneous foam formulation is a fixed combination of calcipotriol and betamethasone (as dipropionate) developed with the aim of improving treatment for patients with psoriasis vulgaris the most common form of psoriasis.

The European submission is based on the phase 3a trial, the PSO-FAST trial, which evaluated the efficacy, safety, itch relief and improvement of itch-related sleep loss across a four week period with Enstilar as well as the phase 2 maximum use systemic exposure safety study of Enstilar.

Kim Kjller, Senior Vice President, Global Development at LEO Pharma, commented:

We believe Enstilar has the potential to provide a new, topical treatment option for patients living with psoriasis. Helping people suffering from skin conditions is at the heart of what we do and this regulatory submission, along with our existing treatment portfolio and patient support offerings such as QualityCareTM, reinforces our commitment and takes another step toward improving quality of life for people living with psoriasis.

In December 2014, a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) for Enstilar

Visit link:

LEO Pharma A/S announces regulatory submission of ENSTILAR for psoriasis in Europe

Marana Aerospace Expands Its Capabilities

MARANA, Ariz., Feb. 10, 2015 /PRNewswire/ –Marana Aerospace Solutions (“MAS”) has announced the expansion of its capabilities with the addition of a complete end of life services solution, a hydraulic actuator overhaul and repair shop and a wheel assembly shop for a wide variety of aircraft applications. MAS currently provides overhaul and repair capabilities for flight controls, engine cowlings & pylons, landing gear doors, landing gear actuators, tubing fabrication and testing, and cargo system components for a variety of aircraft types. According to MAS’ new Senior Vice President of Operations, Greg Emerson, “We continue to add services that reduce our customers’ costs and downtime. Our continued focus is to expand our capabilities to effectively support our customers and theirs.”

In addition to these new capabilities, MAS is investing in additional narrow body tooling during the first quarter, with which to address its customers’ needs particularly in the A320 and 737 families. MAS’ President and CEO, Jim Martin, explained that, “We have listened carefully to our customers, and have paid close attention to the market in North America. We believe this investment, together with some anticipated add on acquisitions, will position us well in 2015 and 2016.”

About Marana Aerospace Solutions: Marana Aerospace Solutions is an FAA Approved FAR Part 145 Repair Station with an unlimited FAA Class IV Airframe Rating. We offer a broad range of maintenance, component, paint and other services for Boeing, Airbus, McDonnell Douglas, Bombardier, Raytheon and Embraer aircraft. We are internationally recognized as the world’s largest commercial aircraft MRO and storage facility, consisting of three maintenance hangars and a large maintenance flight line. Our 6,850-foot runway is suitable for takeoff and landing of all aircraft types, including large commercial and military aircraft. Our maintenance center has 460 acres of ramp and storage area that can accommodate over 400 aircraft, as well as over 35,000 square feet of repair shops for avionics, accessories, composite structures, interior configuration, NDT testing and inspection.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/marana-aerospace-expands-its-capabilities-300033828.html

SOURCE Marana Aerospace Solutions

Go here to see the original:

Marana Aerospace Expands Its Capabilities

Thomas Caskey joins NextCODE

CAMBRIDGE, Mass., Dec. 1,2014 /PRNewswire/ –NextCODE Health, which provides the most proven system for applying genome sequence data to deliver better medicine, today announced the appointment of Dr C Thomas Caskey as senior vice president for medical science and diagnostics. Dr Caskey, who is professor of molecular and human genetics at Baylor School of Medicine and founder of its Medical …

More:

Thomas Caskey joins NextCODE

Overcoming Obstacles to Spread – 2014 Colloquium – Welcome – Video



Overcoming Obstacles to Spread – 2014 Colloquium – Welcome
Visit: http://www.uctv.tv/) John Stobo, MD, Senior Vice President, Health Sciences and Services UC Office of the President delivers welcoming remarks to the 2014 Colloquium. Recorded on 05/02/201…

By: University of California Television (UCTV)

Read more from the original source:

Overcoming Obstacles to Spread – 2014 Colloquium – Welcome – Video

Liberty Global to Roll-Out Pan-European Mobile Platform

Liberty Global Plc (LBTYA), the cable company controlled by billionaire John Malone, plans to offer mobile phone services to customers throughout Europe, taking on carriers such as the U.K.s Vodafone Group Plc.

Liberty Global will put together a so-called mobile virtual network operator system, or MVNO, the name given to companies that use other carriers wireless infrastructure for their own mobile services, Senior Vice President Manuel Kohnstamm said in a interview yesterday in Amsterdam.

Were working on a deep MVNO, and we dont only do that in Austria but in the whole of Europe, Kohnstamm said. Were constructing a pan-European MVNO platform.

Liberty Global will be able to keep margins high because, as a European cable TV operator, the company runs one billing system, one back-office and one back-haul, which connects the core network to the smaller subnetworks, he said. The company is introducing the MVNO network in the Netherlands, Belgium, Switzerland, Austria and the U.K., Kohnstamm said.

Related:

The company has been active on acquisitions in the European cable market in recent years, taking over Virgin Media Inc. in the U.K. in 2013 and agreeing to buy Dutch operator Ziggo NV (ZIGGO) in January.

London-based Liberty Global has now reached a critical mass, Kohnstamm said, which has led the company to having sufficient scale to be competitive on delivering hardware, research and development, technology and content. While the company isnt actively pursuing acquisitions, it hasnt lost interest in potential takeovers.

We will always be interested and look around, Kohnstamm said, adding that he mostly sees a role for small and middle-sized companies.

They are the ones having to compete with Deutsche Telekom, Belgacom and KPN, which also invest and innovate further, Kohnstamm said. For that reason, he eventually sees those companies being just as interested in joining Liberty as Liberty is in them.

Belgiums Telenet Group Holding NV (TNET), which Liberty Global failed to take over after Telenets shareholders rejected a bid in 2013, isnt one of those smaller companies Liberty is aiming for at the moment.

The rest is here:

Liberty Global to Roll-Out Pan-European Mobile Platform

Health Care Basics

ORLANDO, Fla.

For many, signing up for health care hasn’t been as easy as signing the Affordable Care Act into law, as President Barack Obama did in March 2010.

The commercials made it look simple, but frustrations, complications and aggravation were some of the early reactions to the healthcare.gov website.

Those people are very right on, said Rachel Steinberg, Director of Business Development for Orlando Health. I mean, I work in the industry and I see I have 132 options to buy insurance. It’s extremely overwhelming.

Its also time consuming.

And yes, it takes a little bit of homework, Steinberg explained. “A lot of homework, hours, sometimes, of analyzing the options.

Rachel Steinberg’s an expert. She helps businesses understand the Affordable Care Act in Florida.

I’ve heard other technology folks say its easier to keep track of your fantasy football team online than your health care expenses, which is kind of funny because health care is very important, she added.

Jason Altmire also is a health care expert. He was a Congressman when the Affordable Care Act passed.

I voted against the law, said Altmire, who now works for Florida Blue as its Senior Vice President for Public Policy, Government and Community Affairs.

Read more here:

Health Care Basics

IHS Jane’s Aerospace & Defense Site ‘First Stop Destination’ for Industry

LONDON–(BUSINESS WIRE)–

IHS Inc. (IHS), the leading global source of information and analytics, today launched a new free-to-view site specifically designed for the Aerospace and Defense community.

IHSJanes360.com features:

IHS Janes 360 will demonstrate the very best of what IHS Aerospace and Defence offers, making this site the first-stop destination for all defence and security professionals worldwide, said Senior Vice President for Aerospace, Defense & Maritime Michael Dell.

The site is part of a company-wide strategy to highlight, through free content sites, how IHS analysis can help customers grow their businesses. Later this year, IHS will also launch two additional 360 sites supporting the Airports and Maritime sectors.

About IHS Aerospace and Defence: IHS Aerospace and Defence provides professionals with timely and accurate data, analysis and forecasts to support and enhance the complete A&D lifecycle, from program conception and procurement to retirement. For more information about our A&D products and services go to: http://www.ihs.com/products/janes/index.aspx

About IHS (www.ihs.com)

IHS (IHS) is the leading source of information, insight and analytics in critical areas that shape today’s business landscape. Businesses and governments in more than 165 countries around the globe rely on the comprehensive content, expert independent analysis and flexible delivery methods of IHS to make high-impact decisions and develop strategies with speed and confidence. IHS has been in business since 1959 and became a publicly traded company on the New York Stock Exchange in 2005. Headquartered in Englewood, Colorado, USA, IHS is committed to sustainable, profitable growth and employs 6,700 people in 31 countries around the world.

IHS is a registered trademark of IHS Inc. All other company and product names may be trademarks of their respective owners. Copyright 2013 IHS Inc. All rights reserved.

See the original post here:

IHS Jane’s Aerospace & Defense Site ‘First Stop Destination’ for Industry

Client Perspectives: Why Central Bancompany, Inc. Chose ADP to Help Them Navigate Health Care Reform – Video



Client Perspectives: Why Central Bancompany, Inc. Chose ADP to Help Them Navigate Health Care Reform
Christine K. Ellinger, SPHR, Senior Vice President Human Resources, Central Bancompany, Inc., a $9.8 billion Missouri-based bank holding company with 13 full…

By: adp

More here:

Client Perspectives: Why Central Bancompany, Inc. Chose ADP to Help Them Navigate Health Care Reform – Video

Commercial Banker Stephen A. Witt Joins Freedom Bank

FAIRFAX, Va.–(BUSINESS WIRE)–

Freedom Bank of Virginia (Bank) (Bulletin Board:FDVA.OB) announced the addition of Stephen A. Witt as Senior Vice President, Corporate Banking Division. Mr. Witt will be based in the Fairfax office and tasked with fostering new relationships while continuing to provide quality service to our existing clientele. All of us are pleased that Steve joined the Bank and look forward to the contributions he will bring to our team, stated Executive Vice President & Chief Lending Officer Kevin Curtis. Mr. Witt joins Freedom Bank from Virginia Commerce Bank where he was a Senior Vice President and Product Development Manager. Prior to Virginia Commerce Bank, Mr. Witt was employed for two years with WashingtonFirst Bank as Vice President and Business Development Officer / Branch Manager of the Banks Fairfax City office.

About Freedom Bank

Freedom Bank is a local community bank providing a full range of financial services, including credit and deposit products, cash management, and Internet banking services for consumers and businesses. The Bank operates from its headquarters office at 10555 Main Street, Fairfax, Virginia 22030. For more information visit http://www.freedombankva.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130405005749/en/

MULTIMEDIA AVAILABLE:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50604488&lang=en

Follow this link:

Commercial Banker Stephen A. Witt Joins Freedom Bank

Commercial Banker James J. Curry Joins Freedom Bank

FAIRFAX, Va.–(BUSINESS WIRE)–

Freedom Bank of Virginia (Bank) (Bulletin Board:FDVA.OB) announced the addition of James J. Curry as Senior Vice President, Corporate Banking Division. Mr. Curry will be based in the Fairfax office and assist in providing quality service to our existing clientele while fostering new relationships throughout the region. We are very pleased to bring Jim on board, stated Executive Vice President & Chief Lending Officer Kevin Curtis. He brings a wealth of knowledge and will be a great asset to our team. Mr. Curry joins Freedom Bank from Key Bank in Denver, Colorado, where he was Vice President and Senior Business Banker. Prior to his time with Key Bank, Mr. Curry spent six years with WashingtonFirst Bank as a Senior Vice President and Commercial Lender in the Banks Reston and Great Falls offices.

About Freedom Bank

Freedom Bank is a local community bank providing a full range of financial services, including credit and deposit products, cash management, and internet banking services for consumers and businesses. The Bank operates from its headquarters office at 10555 Main Street, Fairfax, Virginia 22030. For more information visit http://www.freedombankva.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130403005845/en/

MULTIMEDIA AVAILABLE:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50602434&lang=en

Read the original post:

Commercial Banker James J. Curry Joins Freedom Bank

B/E Aerospace to Webcast February 25, 2013 Investor Meeting

WELLINGTON, Fla.–(BUSINESS WIRE)–

B/E Aerospace, Inc. (BEAV), the worlds leading manufacturer of aircraft cabin interior products and the worlds leading distributor of aerospace fasteners and consumables, today announced that it will host an investor meeting in Miami, FL on February 25, 2013. Amin J. Khoury, B/E Aerospace founder, Chairman and CEO, Werner Lieberherr, President and COO, and Thomas P. McCaffrey, Senior Vice President and CFO, will host the meeting.

The meeting will be webcast beginning at 8:30 am Eastern time on Monday, February 25, 2013. A live audio broadcast of the presentation will be available on the investor relations page of the Companys website at http://www.beaerospace.com.

About B/E Aerospace, Inc.

B/E Aerospace is the worlds leading manufacturer of aircraft cabin interior products and the worlds leading distributor of aerospace fasteners and consumables. B/E Aerospace designs, develops and manufactures a broad range of products for both commercial aircraft and business jets. B/E Aerospace manufactured products include aircraft cabin seating, lighting systems, oxygen systems, food and beverage preparation and storage equipment, galley systems, and modular lavatory systems. The Company also provides cabin interior reconfiguration, program management and certification services. B/E Aerospace sells and supports its products through its own global direct sales and product support organization. For more information, visit the B/E Aerospace website at http://www.beaerospace.com.

Follow this link:

B/E Aerospace to Webcast February 25, 2013 Investor Meeting

UNE osteopathic school gets new dean

BIDDEFORD, Maine (AP) Maines only medical school has a new dean.

The University of New England says Dr. Douglas Wood takes over as dean of its College of Osteopathic Medicine this Friday.

Wood most recently served as senior vice president of academic affairs at A.T. Still University in Arizona, where he was dean of the School of Osteopathic Medicine from 2005 to 2010.

He served as president of the American Association of Colleges of Osteopathic Medicine from 1995 to 2005, and earlier served as dean of the College of Osteopathic Medicine at Michigan State University.

View original post here:

UNE osteopathic school gets new dean

Agensys and Seattle Genetics Announce Interim Phase I Data from ASG-5ME Clinical Trial for Prostate Cancer

SANTA MONICA, Calif. & BOTHELL, Wash.–(BUSINESS WIRE)–

Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., and Seattle Genetics, Inc. (SGEN) today announced interim data from a phase I clinical trial evaluating ASG-5ME for the treatment of castration-resistant prostate cancer (CRPC). ASG-5ME is an antibody-drug conjugate (ADC) targeting the SLC44A4 antigen that is being co-developed by both companies for the treatment of solid tumors. The data are being presented at the American Society of Clinical Oncology (ASCO) annual meeting being held June 1-5, 2012 in Chicago, IL.

SLC44A4 is an attractive target in prostate cancer and is present in the majority of patients with both localized and metastatic disease, said Leonard Reyno, M.D., Senior Vice President and Chief Medical Officer of Agensys. The current Phase I data demonstrates the tolerability of this antibody drug conjugate and further evaluation of safety and antitumor activity in patients with castration resistant prostate cancer is ongoing.

It is encouraging to observe these preliminary data with ASG-5ME in prostate cancer, a disease for which late-stage patients need additional therapeutic options, said Jonathan Drachman, M.D., Senior Vice President, Research and Translational Medicine of Seattle Genetics. In addition to prostate cancer, our two companies are continuing to evaluate the potential use of ASG-5ME in other solid tumor indications. In parallel, we are collaborating with Agensys to co-develop ASG-22ME, an ADC targeting Nectin-4 for solid tumors.

Phase 1 trial of ASG-5ME in metastatic castration-resistant prostate cancer (CRPC) (Abstract #4568) ASG-5ME is being evaluated in a single-agent phase I clinical trial to determine the maximum tolerated dose (MTD) and to assess the safety, pharmacokinetic profile and antitumor activity of escalating doses of ASG-5ME. At the time of data analysis, 26 patients were enrolled. The median age of the patients was 69.5 years and the median baseline prostate-specific antigen (PSA) level was 82.25.

Key findings, presented by Dr. Michael Morris from Memorial Sloan Kettering Cancer Center in New York, NY, and clinical investigator on the study include:

The phase I trial is ongoing, with enrollment to two expansion cohorts in chemotherapy nave and chemotherapy exposed CRPC patients planned.

Seattle Genetics and Agensys recently completed enrollment in a phase I pancreatic cancer trial of ASG-5ME dosed weekly. The companies plan to evaluate ASG-5ME in patients with gastric cancer based on preclinical expression data.

About ASG-5ME ASG-5ME is an ADC composed of a fully human antibody directed to SLC44A4, a solute carrier antigen family member identified by Agensys to be overexpressed in epithelial cancers, including more than 80 percent of samples derived from patients with prostate, pancreatic and gastric cancers. The antibody is attached to monomethyl auristatin E (MMAE) via an enzyme-cleavable linker using Seattle Genetics proprietary technology. The ADC is designed to be stable in the bloodstream, but to release MMAE upon internalization into SLC44A4-expressing tumor cells, resulting in targeted cell-killing.

Seattle Genetics and Agensys are co-developing and will globally co-commercialize and share profits on a 50:50 basis for ASG-5ME and ASG-22ME. Seattle Genetics also has an option for 50:50 cost and profit-sharing of a third ADC program at the time of investigational new drug submission.

Go here to read the rest:

Agensys and Seattle Genetics Announce Interim Phase I Data from ASG-5ME Clinical Trial for Prostate Cancer